Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Efficacy of venlafaxine extended release in major depressive disorder patients: effect of baseline anxiety symptom severity
Global Med Affairs Pfizer Ltd, Tadworth, England.
Pfizer GEP SLU, Global Med Affairs, Madrid, Spain.
Pfizer Essential Hlth, Clin Stat Grp, New York, NY USA.
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Neuroscience.
Show others and affiliations
2019 (English)In: International Clinical Psychopharmacology, ISSN 0268-1315, E-ISSN 1473-5857, Vol. 34, no 3, p. 110-118Article in journal (Refereed) Published
Abstract [en]

Effects of baseline anxiety on the efficacy of venlafaxine extended release versus placebo were examined in a post hoc pooled subgroup analysis of 1573 patients enrolled in eight short-term studies of major depressive disorder. Anxiety subgroups were defined based on baseline 17-item Hamilton Rating Scale for Depression Item 10 score <3 (low) versus >= 3 (high). Change from baseline to final visit in Montgomery-Asberg Depression Rating Scale total score and Montgomery-Asberg Depression Rating Scale response and remission rates were analyzed. Change from baseline in Montgomery-Asberg Depression Rating Scale total score and response and remission rates was significantly greater for venlafaxine extended release versus placebo in both low and high anxiety subgroups (all P < 0.0001). A statistically significant baseline anxiety by treatment interaction was observed for Montgomery-Asberg Depression Rating Scale total score only (P = 0.0152). The adjusted mean change from baseline in Montgomery-Asberg Depression Rating Scale total score was significantly greater in the high anxiety subgroup versus low anxiety subgroup for patients treated with venlafaxine extended release (-6.27 versus -3.89; P = 0.0440) but not placebo. These results support the efficacy of venlafaxine extended release for major depressive disorder treatment in patients with anxiety symptoms. Copyright (C) 2019 The Author(s). Published by Wolters Kluwer Health, Inc.

Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS , 2019. Vol. 34, no 3, p. 110-118
Keywords [en]
anxiety, major depressive disorder, serotonin-norepinephrine reuptake inhibitor, treatment efficacy, venlafaxine extended release
National Category
Psychiatry
Identifiers
URN: urn:nbn:se:uu:diva-393534DOI: 10.1097/YIC.0000000000000256ISI: 000480700500002PubMedID: 30870236OAI: oai:DiVA.org:uu-393534DiVA, id: diva2:1353883
Available from: 2019-09-24 Created: 2019-09-24 Last updated: 2019-09-24Bibliographically approved

Open Access in DiVA

fulltext(745 kB)25 downloads
File information
File name FULLTEXT01.pdfFile size 745 kBChecksum SHA-512
966769a62218f893751d8a1bbd7799e8c370de46c3969272cae41af210d9c8c22669d66583013b463760d1a912919cb48c5c89ac932b1927b97bd09d1a7f32e8
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Allgulander, Christer
By organisation
Department of Neuroscience
In the same journal
International Clinical Psychopharmacology
Psychiatry

Search outside of DiVA

GoogleGoogle Scholar
Total: 25 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 18 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf